Background: Myxofibrosarcoma (MFS), formerly considered as a myxoid variant of malignant fibrous histiocytoma, is the most common sarcoma of the extremities in adults and is characterized by a high frequency of local recurrence. The clinical behavior of MFS is unpredictable and the efficacy of chemotherapy is still not well documented. Furthermore, given the relatively recent recognition of MFS as a distinct pathologic entity its cellular and molecular biology has still not been extensively studied in patient-derived preclinical models. We examined the molecular biology and treatment outcomes of high-grade, patient-derived MFS primary cultures. Methods: A total of three patient-derived MFS primary cultures were analyzed. We evaluated the role of CD109 expression and also looked for a correlation between transforming growth factor-beta (TGF-β) expression and sensitivity of the primary cultures to different drugs. Results: CD109 was a promising marker for the identification of more aggressive highgrade MFS and a potential therapeutic target. The results also highlighted the potential role of TGF-β in chemoresistance. Pharmacological analysis confirmed the sensitivity of the cultures to chemotherapy. The most active treatments were epirubicin alone and epirubicin in combination with ifosfamide, the latter representing the current standard of care for soft tissue sarcomas (STSs), including MFS. Conclusions: Our results provide a starting point for further research aimed at improving the management of MFS patients undergoing chemotherapy.
Introduction
Myxofibrosarcoma (MFS) is one of the most common soft tissue sarcomas (STSs) usually affecting the extremities in adults. 1 Currently, the World Health Organization describes MFS as a spectrum of malignant fibroblastic lesions with myxoid stroma, pleomorphism and curvilinear vessels. 2, 3 The majority of lesions occur on the lower limbs but have also been reported on the trunk and head/neck region. The retroperitoneum and abdominal cavity are very rare sites of occurrence. Clinically, low-grade lesions show a propensity for multiple local recurrence and are characterized by low metastatic capacity. 4 Conversely, high-grade lesions, exhibit increasing rates of metastatic potential. [1] [2] [3] [4] [5] [6] Furthermore, 15-38% of local MFS recurrences evolve to higher histologic entities with increased metastatic potential. 2 The prognosis for MFS is slightly better than that of other STSs, with an overall incidence of distant metastases ranging from 20% to 25%. 7, 8 At present there are no specific immunohistochemical markers for the standard differential diagnosis of MFS, which is based on the analysis of cytomorphologic findings comprising the presence of a myxoid background, nuclear atypia, pseudolipoblasts and curvilinear blood vessels. These histological characteristics also represent key features for distinguishing MFS from other sarcoma subtypes, for example, liposarcoma, in cases of dubious diagnosis. 9, 10 The current standard of care for localized disease is radical resection with clear surgical margins combined with neoadjuvant or adjuvant radiotherapy. The management of extremity MFS favors organ preservation, with amputation only considered in selected cases. 11 However, despite treatments, local recurrence rates are between 50% and 60%. [12] [13] [14] The use of chemotherapy in metastatic MFS, which represents the standard clinical care, is still limited and outcome remains very poor. As with other STS, no large clinical trials focusing on this tumor have been carried out to date, making it crucial to identify novel molecular markers that can be used for diagnostic purposes but also as new therapeutic targets. In this scenario, patient-derived specimens represent precious tools that have been widely used to focus on tumor pathophysiology and pharmacology. [15] [16] [17] This is particularly evident in the case of rare tumors such as MFS where case series are inevitably small, limiting the number of surgical specimens. Furthermore, the number of commercially available immortalized cell lines is limited. Primary cultures thus represent a promising strategy for improving our understanding of the biology of these malignancies and for tailoring patient treatment.
The above consideration led us to analyze three patient-derived MFS primary cultures. Tumors from patients treated at our institute [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy] were harvested intraoperatively and MFS primary cultures were obtained. The cultures were characterized in terms of gene expression analysis. In particular, we evaluated the potential role of CD109, a transforming growth factor-beta (TGF-β) co-receptor first reported in this histotype by Emori and colleagues in 2015, as a novel marker and therapeutic target in MFS. 18 The authors observed that CD109 was more frequently expressed in high-grade MFS than in low-grade disease. Although no statistically significant correlation was found between CD109 expression and tumor grade, an interesting trend was observed in this specific setting. The above results prompted us to explore the role of CD109 as an indicator of a more aggressive MFS histotype. We also investigated the sensitivity of our primary culture to different drugs currently used in clinical practice or under evaluation for the treatment of STS. Within this context, the expression of TGF-β was evaluated as a potential marker of chemoresistance.
To the best of our knowledge, this is the first study to examine the molecular biology and treatment outcomes of high-grade, patient-derived MFS primary cultures.
Materials and methods

Case series
The study involved three patients with high-grade MFS. All patients underwent surgical treatment performed by an experienced orthopedic surgeon at the Department of Orthopedics of Istituto Ortopedico Rizzoli, Bologna, Italy. Briefly, the tumor mass was surgically excised, as reported in the results section. The protocol was approved by the IRST-Area Vasta Romagna Ethics Committee, approval no. 4751/2015, and performed according to Good Clinical Practice standards and the Declaration of Helsinki. All patients gave written informed consent to take part in the study.
The surgical specimens were analyzed by a sarcoma pathologist (Pathology Unit, MorgagniPierantoni Hospital, Forlì, Italy) and processed within 3 h of surgical resection. Normal tissue characterized by adipose tissue, fascia, vessels and muscle tissue [Suppl. Figure 1 (a) and (b)] obtained from one of the three patients was selected by a sarcoma pathologist and used as study control. In accordance with the protocol, all downstream preclinical analyses were performed at the Osteoncology and Rare Tumors Center [Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS].
Establishment of primary cell culture
Patient-derived MFS cell cultures were isolated from the surgical specimen. Tumor specimens were washed twice in sterile phosphate buffered saline (PBS) and shredded into 1-2 mm 3 pieces with surgical scalpels. The obtained pieces were incubated with a PBS solution of 2 mg/ml collagenase type I (Millipore Corporation, Billerica, MA, USA) at 37°C in stirring conditions for 15 min and then stored overnight at room temperature. The next day the collagenase digestion was blocked by adding Dulbecco's modified Eagle's journals.sagepub.com/home/tam 757 medium (DMEM) supplemented with 10% fetal bovine serum, 1% glutamine and 10% penicillin/ streptomycin.
The cells were isolated from the aggregates using 100-µm sterile filters (CellTrics, Partec, Münster, Germany). Cells were counted and seeded in standard monolayer cultures at a density of 80,000 cells/cm 2 and maintained in complete DMEM medium at 37°C in a 5% CO 2 atmosphere. All the experiments were conducted using low-passage primary cultures and analyzed by an experienced sarcoma pathologist.
Synthesis of three-dimensional collagen scaffolds
The collagen scaffolds were synthesized in our laboratory as previously described, with slight modifications. [19] [20] [21] [22] A 1%-wt suspension of an insoluble type I microfibrillar collagen derived from bovine Achilles tendon (Sigma Aldrich, St. Louis, MO, USA) was prepared in 0.05 M of acetic acid solution (pH 3.2) and precipitated to pH 5.5 by adding 1 M of sodium hydroxide solution, resulting in a homogeneous suspension of fine collagen coprecipitates. The material was then chemically cross-linked with a 1 wt% 1,4-butanediol diglycidyl ether (BDDGE) for 24 h at 25°C to stabilize the collagen matrix and to control porosity and tortuosity. This suspension was blended at 20,000 rpm using an overhead homogenizer for 30 min at 4°C and, after mixing, was centrifuged at 2500 rpm for 5 min to remove air bubbles formed by blending. The mixed solution was frozen for 24 h and then freeze-dried for 24 h.
In order to consolidate the three-dimensional (3D) structure and to yield optimal levels of pore interconnectivity, the structure was freeze-dried with a controlled freezing and heating ramp from 25°C to −35°C and from −35°C to 25°C under vacuum conditions, p = 0.20 mbar. Finally, the scaffolds were sterilized by immersion in ethanol 70% for 1 h followed by three washes in PBS. TUNEL assay DNA fragmentation resulting from apoptotic signals was detected by the terminal deoxynucleotidyl transferase (TdT) nick end labeling (TUNEL) assay, as previously reported. 29 After treatment, cells were washed twice with PBS, fixed in 1% formaldehyde on ice for 15 min and incubated in 70% ice cold ethanol for 1 h. Cells were then washed twice with PBS, permeabilized with 0.1% Triton-X100 for 5 min and incubated with TdT and FITC conjugated dUTP deoxynucleotides 1:1 solution (Roche Diagnostic GmbH, Mannheim, Germany) in a humidified atmosphere for 90 min at 37°C in the dark conditions. Images were captured with an inverted fluorescence microscope.
Immunohistochemical analysis
Statistical analysis
Three independent replicates were performed for each experiment. Data are presented as mean ± standard deviation (SD) or mean ± standard error, as stated, with n indicating the number of replicates. Differences between groups were assessed by a two-tailed Student's t-test and accepted as significant at p < 0.05.
Results
Patient characteristics MF1 history. Patient MF1 was a 66-year old female with a primary diagnosis of high-grade myxofibrosarcoma of the right thigh operated on July 2013 with negative surgical margins.
A chest computed tomography (CT) scan after surgery revealed the presence of bilateral nodules suggestive of lung metastases and subsequently confirmed by positron emission tomography (PET) CT scan with fludeoxyglucose F 18 (FDG). In September 2013, the patient underwent an atypical resection of the bilateral lung lesions, the histological report confirming the presence of adenocarcinoma of the lung, pT2a N0 LV0 G2 R0 staging with mutated K-ras and wild type EGFR. After surgery, there was no evidence of metastatic disease and she was treated with adjuvant chemotherapy for the lung cancer with carboplatin and gemcitabine for six cycles. She was monitored closely and was disease-free for about 9 months.
In February 2015, a new thigh lesion was surgically removed, the histology report indicating a relapse of high-grade myxofibrosarcoma; Ki67 70%; mitotic index 19 mitoses/10 high power fields (HPFs). Adjuvant local radiotherapy was administered.
In September 2015 evidence was found of inguinal lymph node involvement and the patient began chemotherapy with doxorubicin. After three cycles, she obtained a complete response of the lymph node disease and lung progression with the appearance of a new nodule of about 2 cm detected in the right pulmonary lobe. Chemotherapy was stopped and the patient underwent surgery to remove the lung nodule, confirmed as a relapse of the lung adenocarcinoma. The subsequent CT scan revealed progression in the lung, with the appearance of another nodule in the same lung. 
Chemotherapy in high-grade primary myxofibrosarcoma cultures
We assessed the sensitivity of our primary cultures to IFO, EPI and a combination of IFO and EPI, which represents the standard chemotherapy for MFS. We also evaluated the efficacy of trabectedin, a marine-derived, DNA-binding compound, approved for the treatment of patients with advanced STS after failure of anthracyclines, or for those who are not candidates for these agents. 32 In MF1, IFO did not affect survival [ Figure 3 
Discussion
MFS is one of the most common STSs in adults, occurring mainly on the extremities but also on the trunk and head and neck region. Despite having a better prognosis than other subtypes, the clinical behavior of MFS is characterized by a propensity for multiple local recurrences and a lower incidence of distant metastases. 4 The diagnosis of MFS is based on the presence of specific morphological features including prominent curvilinear blood vessels, myxoid stroma, spindle and pleomorphic cells. There are still no specific diagnostic markers available. The cornerstone of therapy for localized disease is surgery, with radiotherapy administered pre-or postsurgery in selected cases. However, local recurrences are frequently reported. 33 The standard of care for metastatic MFS is chemotherapy, but outcomes are still very limited.
A better understanding of the molecular biology and treatment outcomes of high-grade MFS is needed to improve patient management. In the field of translational research, primary cultures provide a valuable material for studying tumor pathophysiology and pharmacology. This is especially true for rare tumors such as STS in which clinical outcome is very poor and large clinical trials are limited. In the present work, near-patient cells derived from high-grade MFS were harvested immediately after surgery. The cells were seeded in 3D scaffolds to confirm the establishment of MFS patient-derived cultures. The assessment of the morphological features in H&E-stained 3D primary cultures was reviewed by an experienced sarcoma pathologist who confirmed the diagnosis of high-grade MFS.
As previously mentioned, MFS was recently acknowledged as a separate pathologic entity and as such there is still little documentation of its clinical behavior and patient outcome. It is therefore crucial to identify a marker that can act as a tool for diagnosis but as a therapeutic target.
TGF-β is a multifunctional cytokine belonging to the transforming growth factor superfamily which is involved in several physiological and tumorassociated pathways. It also appears to have a role in chemotherapy resistance, as reported in several tumors including breast cancer and squamous cell carcinoma. 34, 35 CD109, a TGF-β co-receptor, is a cell surface glycoprotein expressed in endothelial cells, hematopoietic cells, and several tumors. Its activation is mediated by T-lymphocytes, a subpopulation of bone marrow CD34+ cell and platelets. CD109 promotes TGF-β receptor degradation and inhibits TGF-β/Smad signaling. [36] [37] [38] [39] The prognostic significance of CD109 overexpression has been reported in several tumors including breast cancer, 40, 41 squamous cell/adenosquamous carcinoma of the lung, esophagus, uterus and gallbladder, [42] [43] [44] [45] and also STS. Recently, the prognostic impact of CD109 expression was also reported in MFS. 18 Emori and colleagues observed 5-year overall survival rates of 77% and 0% for CD109-negative and CD109-positive patients, respectively. Although they did not find a statistically significant correlation between CD109 expression and tumor grade (p = 0.2877) an interesting trend was seen for high-grade MFS which showed higher positivity for CD109 than grade 1 and 2.
Furthermore, although CD109 mRNA overexpression is observed in various sarcoma cell lines, it is weakly expressed in normal adult tissues. 46 On the basis of these results, we conducted an analysis of CD109 and TGF-β gene expression profiling. CD109 was overexpressed in all highgrade MFS primary cultures with respect to matched patient-derived normal tissue. Interestingly, CD109 overexpression was markedly higher in the primary tumor MF3 (663-fold higher compared with the normal tissue) than in local recurrences MF1 and MF2 (24-and 72-fold higher than that of normal tissue) [ Figure 2 (a) and (c)]. These data are consistent with findings from other studies in which CD109, albeit preferentially expressed during the early stages of tumorigenesis in tumors such as oral and urothelial carcinomas, was also associated with advanced stage in STS. 18 We hypothesized that the lower CD109 expression observed in local recurrences MF1 and MF2 could be correlated to disease relapse, suggesting a similar behavior of the advanced stage. Further research is needed to confirm this. Although MF1 and MF2 were both local recurrences, differences in CD109 gene expression were detected which could be attributable to the variability of the specimens and the clinical characteristics of patients.
The potential prognostic role of CD109 was not investigated in this study due to the small sample size and the limited patient follow up. Of note, patient MF1, who had the longest follow up, died in 2016 after developing MFS-derived lung metastases. This would seem to correlate with the results presented by Emori and colleagues, who found that CD109 overexpression was significantly associated with distant metastases (p = 0.01), otherwise further analysis are needed to confirm this. Furthermore, immunohistochemical analysis of CD109 in the primary cultures [ Figure 2 (d)] confirmed its higher expression than in normal tissue (H), suggesting its potential role as an aid to support the identification of highgrade MFS.
It has also been reported that CD109 negatively regulates TGF-β pathway through TGF-β receptor degradation in numerous diseases, including fibrosis and cancer. 47 Given that TGF-β regulates its own expression by a positive feedback mechanism, 48 we decided to analyze it in our specimens, observing that it was markedly overexpressed in MF2 with respect to MF1 and MF3. Furthermore, TGF-β expression was downregulated when CD109 was overexpressed, suggesting that CD109 exerts a negative effect on TGF-β expression and its signaling pathway [ Figure 2(b) ].
Further analyses are needed to elucidate the molecular mechanisms of both CD109 and TGF-β expression in MFS. In this regard, it would also be useful to compare CD109 expression with that of primary cultures of other STS subtypes to assess the potential role of CD109 in the differential diagnosis of MFS. Furthermore, TGF-β expression in STS histotypes could be studied to clarify whether it plays a part in resistance to chemotherapy.
In our study, patient-derived cultures were treated with some of the drugs currently used for STS to investigate the impact of chemotherapy on MFS. The chemosensitivity assay revealed that MF1 and MF3, albeit clinically different, responded in a similar way to the drugs. Conversely, MF2 generally exhibited a lower response to the treatments [ Figure 3(d)] . Notably, the MF2 specimen was characterized by the presence of markedly pleomorphic areas ( Figure 1 ) and a higher expression of TGF-β than the other two specimens [ Figure  2(b) ], which could explain its lower sensitivity to chemotherapy. Further analyses are needed to confirm these observations.
The most active regimens in our analysis were EPI alone or in combination with IFO, both of which proved significant in all of the cultures. Anthracycline-based chemotherapy represents the current standard first-line treatment of STS, including MFS. Clinically, the combination of anthracyclines and IFO is widely used to increase the clinical benefit of patients. In other settings, anthracyclines alone are preferred, especially for patients undergoing palliative care. 49, 50 Interestingly, the antiproliferative activity of IFO was more effective in MF2 than in the other cultures, suggesting a higher sensitivity of this drug in high-grade MFS with markedly pleomorphic areas. 51, 52 Trabectedin showed a higher cytotoxic activity in MF1 and MF3 than in MF2 cultures. The efficacy of this drug in STS, in particular the myxoid liposarcoma histotype, has been demonstrated in numerous clinical trials, but there are also reports of its activity in other sarcoma subtypes. [53] [54] [55] Although, there is limited evidence of the impact of trabectedin on MFS, 56 our results are suggestive of some activity in this STS subtype. Moreover, its antitumor activity appears to be related to its direct effect on both cancer cells and the tumor microenvironment. Immunomodulatory and anti-angiogenetic effects have also been reported. 57, 58 Given the pleiotropic mechanism of action of trabectedin, we can thus hypothesize that its full spectrum of activity was underestimated in our in vitro models. The TUNEL assay was performed to analyze the number of apoptotic cells after treatment with each of the tested drugs. Results were consistent with those obtained from the cytotoxicity assay, confirming the sensitivity of the MFS patient-derived cultures to most of the drugs (Figure 4 ).
In conclusion, the results from the present study highlight the importance of using near-patient models in STS research to obtain a better understanding of the biology of the disease. Moreover, our findings increase MFS cell characterization which, given the few MFS cell lines commercially available, 59 could represent a starting point for further studies on this poorly explored cancer. Gene and protein expression analysis indicated journals.sagepub.com/home/tam 765 that CD109 could represent an aid to the diagnosis of high-grade MFS and a potential therapeutic target for this histotype. Our findings also suggest that TGF-β expression might be a useful marker for resistance to chemotherapy. However, further analyses are needed to elucidate the role of these genes in the management of MFS patients. However, the study is not without limitations, that is, small sample size, cellular heterogeneity in primary cultures and decreasing reliability of the preclinical model over time to recapitulate the tumor microenvironment.
Finally, our results provide a starting point for further investigations aimed at improving the current management of MFS patients undergoing chemotherapy.
